A Look At Progyny (PGNY) Valuation After A Steep Three Month Share Price Pullback

Simply Wall St.04-04

AdvertisementProgyny stock performance sets the stage for closer review Progyny (PGNY) has been under pressure, with the share price showing a 1.5% decline over the past day, a 5.8% decline over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625613798?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151","is_english":true,"pubTime":"2026-04-04 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625613798","market":"nz","top_or_hot":-1,"title":"A Look At Progyny (PGNY) Valuation After A Steep Three Month Share Price Pullback","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementProgyny stock performance sets the stage for closer review Progyny (PGNY) has been under pressure, with the share price showing a 1.5% decline over the past day, a 5.8% decline over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/a-look-at-progyny-pgny-valuation-after-a-steep-three-month-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Progyny (PGNY) Valuation After A Steep Three Month Share Price Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Progyny (PGNY) Valuation After A Steep Three Month Share Price Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-04 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/a-look-at-progyny-pgny-valuation-after-a-steep-three-month-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementProgyny stock performance sets the stage for closer review Progyny (PGNY) has been under pressure, with the share price showing a 1.5% decline over the past day, a 5.8% decline over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/a-look-at-progyny-pgny-valuation-after-a-steep-three-month-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4154","symbol_name":"管理型保健护理","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/a-look-at-progyny-pgny-valuation-after-a-steep-three-month-s","article_id":"2625613798","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-pgny/progyny/news/a-look-at-progyny-pgny-valuation-after-a-steep-three-month-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625613798","pubTimestamp":1775312266,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Progyny stock performance sets the stage for closer review\nProgyny (PGNY) has been under pressure, with the share price showing a 1.5% decline over the past day, a 5.8% decline over the past month, and a 35.5% decline over the past 3 months.\nThese moves, alongside recent financial figures such as US$1.29b in revenue and US$58.52m in net income, are prompting some investors to reassess what they are paying for the company’s fertility and family benefits business.\nSee our latest analysis for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4154":"管理型保健护理","PGNY":"Progyny"},"translate_title":"股价三个月大幅回调后的Progyny(PGNY)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGNY":1.5},"content_text":"AdvertisementProgyny stock performance sets the stage for closer review Progyny (PGNY) has been under pressure, with the share price showing a 1.5% decline over the past day, a 5.8% decline over the past month, and a 35.5% decline over the past 3 months. These moves, alongside recent financial figures such as US$1.29b in revenue and US$58.52m in net income, are prompting some investors to reassess what they are paying for the company’s fertility and family benefits business. See our latest analysis for Progyny. With the share price at US$16.60 and a year to date share price return of a 35.5% decline, momentum has clearly faded, and the 1 year total shareholder return of a 26.55% decline underlines how sentiment has cooled despite Progyny’s scale in US fertility benefits. If Progyny’s recent pullback has you rethinking your watchlist, it can be helpful to see what else is moving in related areas such as healthcare AI, starting with 36 healthcare AI stocks. With Progyny trading at US$16.60, generating US$1.29b in revenue and US$58.52m in net income, the key question is whether this selloff leaves the stock undervalued or if the market already reflects its future growth potential. Most Popular Narrative: 46.3% Undervalued Progyny’s most followed narrative sets a fair value of $30.91 per share, compared with the last close at $16.60. This frames a wide valuation gap that hinges on assumptions about future growth and profitability.  Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.  Read the complete narrative. Want to see what kind of revenue growth, margin uplift, and future earnings multiple are needed to justify that gap? The narrative sets out a detailed earnings path, a richer product mix, and a specific profit profile that all need to line up for $30.91 to make sense. Result: Fair Value of $30.91 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear swing factors, including employer cost cutting that could limit fertility benefit adoption and rising competition that might pressure Progyny’s margins and client growth. Find out about the key risks to this Progyny narrative. Another View: Market Pricing Looks Less Generous The first narrative leans on future cash flows to argue Progyny could be materially undervalued, yet today the shares trade on a P/E of 22.2x versus 18.2x for peers and a fair ratio of 21.8x. That premium hints at less cushion if expectations are wrong, so which signal do you trust? For a closer look at how this earnings based view is built and what might need to change for the current price to better line up with the fair ratio, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:PGNY P/E Ratio as at Apr 2026Next Steps The recent pullback and mixed valuation signals might leave you conflicted. Do not wait to review the details for yourself and weigh the upside case in the 3 key rewards Ready to hunt for your next opportunity? If Progyny is already on your radar, do not stop there. Broadening your ideas list can sharpen your decisions and highlight opportunities you might otherwise miss.  Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems that pair quality fundamentals with room for market attention to catch up. Focus on financial resilience and consistent balance sheet strength using the solid balance sheet and fundamentals stocks screener (40 results) to surface companies with sturdier foundations. Prioritise stability and lower volatility by screening for 68 resilient stocks with low risk scores that may help anchor a more balanced portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625613798","isCrawlerRequest":true}